US FDA approves Sanofi's bleeding disorder therapy
The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of ...
Sanofi’s Easier to Use Hemophilia Drug Approved by US FDA
Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...
Fierce Pharma1d
Sanofi's versatile Qfitlia scores FDA nod to enter crowded hemophilia market
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
Zacks.com on MSN3d
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability ...
pharmaphorum2d
FDA fast-tracks Sanofi's experimental chlamydia vaccine
Jean-François Toussaint, Sanofi's global head of vaccines R&D, speaking at a conference at the company's site in Lyon last ...
GlobalData on MSN3d
FDA fast tracks Sanofi’s mRNA vaccine for chlamydia
Sanofi will soon commence a Phase I/II trial with its vaccine candidate to start generating immunogenicity data.
BioPharma Dive1d
FDA approves first-of-its-kind RNA drug for hemophilia
The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...
FDA approves Sanofi treatment for hemophilia A or B
The U.S. Food and Drug Administration approved Qfitlia for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult ...
Medical Dialogues19h
USFDA approves Sanofi Qfitlia for hemophilia A or B with or without inhibitors
Paris: Sanofi has announced that the Company has received approval from the US Food and Drug Administration (FDA) for Qfitlia ...
AbbVie Vs. Sanofi: Which Is The Better Investment Right Now
Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...
EconoTimes18h
Sanofi’s New Hemophilia Drug Qfitlia Gains FDA Approval with Breakthrough Bimonthly Dosing
The U.S. Food and Drug Administration (FDA) has approved Qfitlia, a groundbreaking hemophilia treatment by French pharmaceutical giant Sanofi (NASDAQ: SNY). Designed for patients aged 12 and older ...